BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 38686207)

  • 1. The clinical value of iodine-125 seed implantation in the treatment of iodine-refractory differentiated thyroid carcinoma.
    Wan Q; Tan L; Tang X; Wang W; Su Y; Wu Z; Ke M; Chen Z
    Front Endocrinol (Lausanne); 2024; 15():1327766. PubMed ID: 38686207
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The value of diagnostic whole-body scanning and serum thyroglobulin in the presence of elevated serum thyrotropin during follow-up of anti-thyroglobulin antibody-positive patients with differentiated thyroid carcinoma who appeared to be free of disease after total thyroidectomy and radioactive iodine ablation.
    Rosario PW; Mineiro Filho AF; Lacerda RX; dos Santos DA; Calsolari MR
    Thyroid; 2012 Feb; 22(2):113-6. PubMed ID: 22224815
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative thyroglobulin response to radioactive iodine treatment in predicting radioactive iodine-refractory thyroid cancer with pulmonary metastasis.
    Wang C; Zhang X; Li H; Li X; Lin Y
    PLoS One; 2017; 12(7):e0179664. PubMed ID: 28704384
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical value of
    Wenwen Z; Guoxiu L; Hao S; Wang Z; Ji L; Ge X; Li G; Wang Y; Zhang G
    Appl Radiat Isot; 2023 Sep; 199():110868. PubMed ID: 37392614
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Markedly elevated serum preoperative thyroglobulin predicts radioiodine-refractory thyroid cancer.
    Cheng X; Xu S; Zhu Y; Wu J; Bao J; Yu H; Zhang L
    Eur J Clin Invest; 2022 Apr; 52(4):e13721. PubMed ID: 34855206
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An enhanced treatment effect can be expected from a higher serum thyroglobulin level after radioactive iodine therapy.
    Choi JH; Lim I; Lee I; Byun BH; Kim BI; Choi CW; Lim SM
    Ann Nucl Med; 2019 Feb; 33(2):128-134. PubMed ID: 30382500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Importance of postoperative stimulated thyroglobulin level at the time of 131I ablation therapy for differentiated thyroid cancer.
    Hasbek Z; Turgut B; Kilicli F; Altuntas EE; Yucel B
    Asian Pac J Cancer Prev; 2014; 15(6):2523-7. PubMed ID: 24761858
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimization of serum thyroglobulin measured at different time points for prognostic evaluation in differentiated thyroid carcinoma patients.
    Mutsuddy P; Jeon S; Yoo SW; Zhang Y; Chowdhury MSA; Kim J; Song HC; Bom HS; Min JJ; Kwon SY
    Medicine (Baltimore); 2020 Apr; 99(14):e19652. PubMed ID: 32243397
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An International Phase 2 Study of Pazopanib in Progressive and Metastatic Thyroglobulin Antibody Negative Radioactive Iodine Refractory Differentiated Thyroid Cancer.
    Bible KC; Menefee ME; Lin CJ; Millward MJ; Maples WJ; Goh BC; Karlin NJ; Kane MA; Adkins DR; Molina JR; Donehower RC; Lim WT; Flynn PJ; Richardson RL; Traynor AM; Rubin J; LoRusso PM; Smallridge RC; Burton JK; Suman VJ; Kumar A; Voss JS; Rumilla KM; Kipp BR; Chintakuntlawar AV; Harris P; Erlichman C
    Thyroid; 2020 Sep; 30(9):1254-1262. PubMed ID: 32538690
    [No Abstract]   [Full Text] [Related]  

  • 10. Long-term course and predictive factors of elevated serum thyroglobulin and negative diagnostic radioiodine whole body scan in differentiated thyroid cancer.
    Alzahrani AS; Mohamed G; Al Shammary A; Aldasouqi S; Abdal Salam S; Shoukri M
    J Endocrinol Invest; 2005 Jun; 28(6):540-6. PubMed ID: 16117196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy analysis of (131)I therapy and predictive value of preablation stimulated thyroglobulin for lung metastases from differentiated thyroid cancer.
    Wu S; Wang H
    Ann Endocrinol (Paris); 2013 Feb; 74(1):40-4. PubMed ID: 23337017
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thyroglobulin fluctuations in patients with iodine-refractory differentiated thyroid carcinoma on lenvatinib treatment - initial experience.
    Werner RA; Lückerath K; Schmid JS; Higuchi T; Kreissl MC; Grelle I; Reiners C; Buck AK; Lapa C
    Sci Rep; 2016 Jun; 6():28081. PubMed ID: 27306607
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preoperative undetectable serum thyroglobulin in differentiated thyroid carcinoma: incidence, causes and management strategy.
    Giovanella L; Ceriani L; Ghelfo A; Maffioli M; Keller F
    Clin Endocrinol (Oxf); 2007 Oct; 67(4):547-51. PubMed ID: 17561976
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-thyroglobulin antibodies do not significantly increase the risk of finding iodine avid metastases on post-radioactive iodine ablation scan in low-risk thyroid cancer patients.
    Nabhan F; Porter K; Senter L; Ringel MD
    J Endocrinol Invest; 2017 Sep; 40(9):1015-1021. PubMed ID: 28510122
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Postoperative-stimulated serum thyroglobulin measured at the time of 131I ablation is useful for the prediction of disease status in patients with differentiated thyroid carcinoma.
    Lee JI; Chung YJ; Cho BY; Chong S; Seok JW; Park SJ
    Surgery; 2013 Jun; 153(6):828-35. PubMed ID: 23489940
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum thyrotropin level of 30 μIU/mL is inadequate for preablative thyroglobulin to serve as a prognostic marker for differentiated thyroid cancer.
    Zhao T; Liang J; Guo Z; Li J; Lin Y
    Endocrine; 2016 Jul; 53(1):166-73. PubMed ID: 26782372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive Value of Clinical and Pathological Characteristics for Metastatic Radioactive Iodine-Refractory Differentiated Thyroid Carcinoma: A 16-year Retrospective Study.
    Chai J; Zhang R; Zheng W; Zhang G; Jia Q; Tan J; Meng Z; Wang R
    Front Endocrinol (Lausanne); 2022; 13():930180. PubMed ID: 35846335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term surveillance of papillary thyroid cancer patients who do not undergo postoperative radioiodine remnant ablation: is there a role for serum thyroglobulin measurement?
    Durante C; Montesano T; Attard M; Torlontano M; Monzani F; Costante G; Meringolo D; Ferdeghini M; Tumino S; Lamartina L; Paciaroni A; Massa M; Giacomelli L; Ronga G; Filetti S;
    J Clin Endocrinol Metab; 2012 Aug; 97(8):2748-53. PubMed ID: 22679061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stimulated thyroglobulin level at ablation in differentiated thyroid cancer: the impact of treatment preparation modalities and tumor burden.
    Ciappuccini R; Hardouin J; Heutte N; Vaur D; Quak E; Rame JP; Blanchard D; de Raucourt D; Bardet S
    Eur J Endocrinol; 2014 Aug; 171(2):247-52. PubMed ID: 24866576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive value of preablation stimulated thyroglobulin and thyroglobulin/thyroid-stimulating hormone ratio in differentiated thyroid cancer.
    Lin Y; Li T; Liang J; Li X; Qiu L; Wang S; Chen Y; Kang Z; Li F
    Clin Nucl Med; 2011 Dec; 36(12):1102-5. PubMed ID: 22064080
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.